#Pharmaceuticals

Anebulo Pharmaceuticals, Inc. filed for delisting after significant financial setbacks reported in its February 12, 2026, filing.

Cybin Inc. was delisted from the NYSE American LLC on January 2, 2026, following a notification of removal from listing due to compliance issues.

Carisma Therapeutics Inc. (CARM) faced a decline in investor confidence leading to its eventual delisting after a failed strategic license agreement and subsequent financial instability.

Clearside Biomedical, Inc. filed for Chapter 11 bankruptcy on November 25, 2025, following sustained financial difficulties.

Opthea Ltd was delisted from Nasdaq on November 10, 2025, due to non-compliance with audit committee requirements.

On November 10, 2025, Genfit S.A. was delisted from Nasdaq following its voluntary withdrawal of American Depository Shares, impacted by setbacks in clinical trials.

Adaptimmune Therapeutics PLC voluntarily delisted from Nasdaq in October 2025 due to compliance issues with listing standards.

Third Harmonic Bio, Inc. voluntarily dissolved and delisted from Nasdaq following stockholder approval on June 5, 2025, with a formal Certificate of Dissolution filed on July 31, 2025.

HOOKIPA Pharma Inc. liquidated after selling key assets to Gilead Sciences and dissolving the company following approval from stockholders, marking the end of its clinical-stage pursuits.

Chrome Holding Co. (MEHCQ), a SPAC aiming to merge with 23andMe, failed to complete its Business Combination and was subsequently delisted.

Vincerx Pharma, Inc. was delisted from Nasdaq following post-merger operational challenges leading to significant declines in its stock performance.

Enzo Biochem Inc. was delisted after announcing a merger, proposed to be completed on August 19, 2025, at a price of $0.70 per share.

Omega Therapeutics, Inc. filed for Chapter 11 bankruptcy on February 10, 2025, leading to its subsequent delisting from Nasdaq on February 25, 2025.

Vaccinex, Inc. (VCNX) was delisted from Nasdaq following executive turnover and compliance issues reported in SEC filings.

Achilles Therapeutics plc voluntarily delisted from Nasdaq on March 11, 2025, following disappointing clinical trial results and declining investor confidence.

Syros Pharmaceuticals, Inc. repaid $6 million in debt to Oxford Finance on February 28, 2025, signaling financial distress and subsequent delisting from Nasdaq.

Eagle Pharmaceuticals, Inc. was delisted from Nasdaq on October 3, 2024, and subsequently began trading on the OTC Expert Market.

Finch Therapeutics Group, Inc. was delisted from Nasdaq after a 'public shell' determination, now moving towards OTC trading amid significant operational challenges.

Guardion Health Sciences, Inc. was delisted following plans for liquidation after a failed strategic transition.

Calliditas Therapeutics AB was delisted from Nasdaq on September 20, 2024, as per regulatory compliance under SEC provisions.

MorphoSys AG was delisted from the Nasdaq Stock Market following the filing of Form 25 on July 25, 2024, due to its compliance with exchange rules for voluntary withdrawal.

Vaxxinity, Inc. voluntarily delisted from the Nasdaq and deregistered its Common Stock on April 19, 2024, due to regulatory compliance issues and business challenges.

Ampio Pharmaceuticals, Inc. was dissolved on August 16, 2024, following a history of regulatory and financial challenges, culminating in stockholder derivative actions and an eventual settlement.

LianBio announced its operational wind down and delisting from Nasdaq following a strategic review, with key actions outlined in its Form 8-K on February 13, 2024.